Myriad Genetics (MYGN) Short Interest Ratio & Short Volume $10.39 -0.34 (-3.17%) Closing price 04:00 PM EasternExtended Trading$10.64 +0.24 (+2.36%) As of 06:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Myriad Genetics Short Interest DataMyriad Genetics (MYGN) has a short interest of 5.43 million shares, representing 6.09% of the float (the number of shares available for trading by the public). This marks a 11.73% increase in short interest from the previous month. The short interest ratio (days to cover) is 5.0, indicating that it would take 5.0 days of the average trading volume of 1.18 million shares to cover all short positions.Current Short Interest5,430,000 sharesPrevious Short Interest4,860,000 sharesChange Vs. Previous Month+11.73%Dollar Volume Sold Short$79.06 millionShort Interest Ratio5.0 Days to CoverLast Record DateFebruary 15, 2025Outstanding Shares91,035,000 sharesShort Percent of Float6.09%Today's Trading Volume1,038,495 sharesAverage Trading Volume1,176,442 sharesToday's Volume Vs. Average88% Short Selling Myriad Genetics? Sign up to receive the latest short interest report for Myriad Genetics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartMYGN Short Interest Over TimeMYGN Days to Cover Over TimeMYGN Percentage of Float Shorted Over Time Myriad Genetics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 2/15/20255,430,000 shares $79.06 million +11.7%6.1%5 $14.56 1/31/20254,860,000 shares $61.58 million +1.0%N/A4.7 $12.67 1/15/20254,810,000 shares $63.25 million +0.6%N/A4.9 $13.15 12/31/20244,780,000 shares $65.53 million +42.7%N/A5.1 $13.71 12/15/20243,350,000 shares $48.34 million -1.2%N/A3.7 $14.43 11/30/20243,390,000 shares $55.16 million -8.1%N/A4.2 $16.27 11/15/20243,690,000 shares $56.27 million -17.6%N/A4.5 $15.25 10/31/20244,480,000 shares $98.38 million -0.2%N/A6.3 $21.96 10/15/20244,490,000 shares $107.67 million +7.2%N/A6.4 $23.98 9/30/20244,190,000 shares $114.76 million +6.4%N/A5.7 $27.39 Get the Latest News and Ratings for MYGN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Myriad Genetics and its competitors with MarketBeat's FREE daily newsletter. 9/15/20243,940,000 shares $108.70 million No ChangeN/A5 $27.59 8/31/20243,940,000 shares $111.62 million +1.6%N/A5 $28.33 8/15/20243,880,000 shares $108.06 million -11.6%N/A5.1 $27.85 7/31/20244,390,000 shares $122.79 million +14.3%N/A5.1 $27.97 7/15/20243,840,000 shares $102.30 million -16.7%N/A4.7 $26.64 6/30/20244,610,000 shares $112.76 million -24.3%N/A5.9 $24.46 6/15/20246,090,000 shares $141.29 million +26.6%N/A8.1 $23.20 5/31/20244,810,000 shares $109.48 million -5.7%N/A6.7 $22.76 5/15/20245,100,000 shares $125.77 million -14.3%N/A6.9 $24.66 4/30/20245,950,000 shares $116.44 million +8.2%N/A8.6 $19.57 4/15/20245,500,000 shares $105.44 million -3.0%N/A9 $19.17 3/31/20245,670,000 shares $120.88 million +18.1%N/A8.9 $21.32 3/15/20244,800,000 shares $101.57 million +20.0%N/A7.5 $21.16 2/29/20244,000,000 shares $83.72 million +8.1%N/A6 $20.93 2/15/20243,700,000 shares $87.28 million -0.3%N/A5.8 $23.59 1/31/20243,710,000 shares $79.36 million -2.9%N/A5.4 $21.39 1/15/20243,820,000 shares $75.90 million -10.3%6.0%5.4 $19.87 12/31/20234,260,000 shares $81.54 million -14.8%N/A6.4 $19.14 12/15/20235,000,000 shares $103.70 million +4.4%N/A7.4 $20.74 11/30/20234,790,000 shares $91.44 million -2.2%N/A7.4 $19.09 11/15/20234,900,000 shares $85.36 million -14.8%N/A8 $17.42 10/31/20235,750,000 shares $89.59 million +4.0%N/A10.4 $15.58 10/15/20235,530,000 shares $80.41 million +11.9%N/A10.6 $14.54 9/30/20234,940,000 shares $79.24 million +1.7%N/A9.5 $16.04 9/15/20234,860,000 shares $80.72 million +9.0%N/A9.7 $16.61 8/31/20234,460,000 shares $79.61 million +15.0%N/A9.2 $17.85 8/15/20233,880,000 shares $68.60 million -2.8%N/A7.5 $17.68 7/31/20233,990,000 shares $89.18 million -5.5%N/A7.6 $22.35 7/15/20234,220,000 shares $94.95 million +3.9%N/A8 $22.50 6/30/20234,060,000 shares $94.11 million -0.5%N/A7.3 $23.18Trump doesn’t give a damn (Ad)Porter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met with one of Trump’s longest-serving advisors. We helped put together a plan to help investors capitalize on Trump’s election. And we found out these 10 stocks are the most likely to boom…Go here now to find out the names of these 10 stocks. 6/15/20234,080,000 shares $93.60 million -3.3%N/A7.3 $22.94 5/31/20234,220,000 shares $93.09 million +11.9%N/A7.2 $22.06 5/15/20233,770,000 shares $70.95 million +2.5%N/A6.1 $18.82 4/30/20233,680,000 shares $78.35 million -1.6%N/A6 $21.29 4/15/20233,740,000 shares $83.29 million -25.9%N/A6.2 $22.27 3/31/20235,050,000 shares $117.31 million -2.7%N/A8.4 $23.23 3/15/20235,190,000 shares $121.08 million +15.9%N/A7.4 $23.33 2/28/20234,480,000 shares $84.76 million +10.6%N/A6.1 $18.92 2/15/20234,050,000 shares $77.96 million +22.7%N/A5.9 $19.25 1/31/20233,300,000 shares $65.08 million +2.8%N/A4.6 $19.72 1/15/20233,210,000 shares $59.93 million -9.6%N/A4.3 $18.67 12/30/20223,550,000 shares $51.51 million -8.3%N/A4.8 $14.51 12/15/20223,870,000 shares $65.52 million +13.5%N/A5.9 $16.93 11/30/20223,410,000 shares $69.09 million -16.0%N/A6 $20.26 11/15/20224,060,000 shares $84.77 million +5.5%N/A7.4 $20.88 10/31/20223,850,000 shares $79.85 million +1.1%N/A7.3 $20.74 10/15/20223,810,000 shares $71.21 million +0.8%N/A7.7 $18.69 9/30/20223,780,000 shares $72.12 million -3.8%N/A7.3 $19.08 9/15/20223,930,000 shares $84.57 million +1.6%N/A7.7 $21.52 8/31/20223,870,000 shares $86.46 million -7.9%N/A7.3 $22.34 8/15/20224,200,000 shares $117.10 million +15.4%N/A7.7 $27.88 7/31/20223,640,000 shares $96.02 million -16.3%4.7%6.3 $26.38 7/15/20224,350,000 shares $95.61 million +23.6%5.7%7.7 $21.98 6/30/20223,520,000 shares $63.96 million -4.1%4.6%6.6 $18.17 6/15/20223,670,000 shares $61.77 million +0.3%4.8%6.8 $16.83 5/31/20223,660,000 shares $70.42 million -5.2%4.8%6.5 $19.24 5/15/20223,860,000 shares $86.35 million +14.2%5.0%6.9 $22.37 4/30/20223,380,000 shares $69.29 million +1.2%4.4%6.4 $20.50 4/15/20223,340,000 shares $80.09 million -7.5%4.4%6.4 $23.98 3/31/20223,610,000 shares $90.97 million -10.4%4.7%6.6 $25.20 3/15/20224,030,000 shares $96.88 million -2.7%5.3%7.4 $24.04 2/28/20224,140,000 shares $100.93 million +0.2%5.4%7.4 $24.38 2/15/20224,130,000 shares $112.13 million -4.0%5.4%7.5 $27.15 1/31/20224,300,000 shares $113.05 million +12.0%5.6%7.6 $26.29 1/15/20223,840,000 shares $106.71 million +6.1%5.0%6.7 $27.79 12/31/20213,620,000 shares $99.91 million -9.1%4.7%7 $27.60 12/15/20213,980,000 shares $107.46 million -2.7%5.2%7.9 $27.00 11/30/20214,090,000 shares $105.77 million +5.7%5.3%9.5 $25.86 11/15/20213,870,000 shares $114.51 million -9.2%5.0%9 $29.59 10/29/20214,260,000 shares $131.08 million -8.8%5.5%10.4 $30.77 10/15/20214,670,000 shares $148.23 million -1.5%6.2%10.9 $31.74 9/30/20214,740,000 shares $153.05 million -2.9%6.3%9.6 $32.29 9/15/20214,880,000 shares $159.67 million -7.8%6.4%8.6 $32.72 8/31/20215,290,000 shares $189.28 million -5.0%7.0%9.1 $35.78 8/13/20215,570,000 shares $182.64 million -4.6%7.4%9.6 $32.79 7/30/20215,840,000 shares $184.72 million -7.5%7.8%9.8 $31.63 7/15/20216,310,000 shares $197.25 million +18.4%8.4%11 $31.26 6/30/20215,330,000 shares $162.99 million -0.7%7.1%9.4 $30.58 6/15/20215,370,000 shares $160.89 million -0.4%7.2%9.8 $29.96 5/28/20215,390,000 shares $154.42 million -5.3%7.2%9.5 $28.65Trump doesn’t give a damn (Ad)Porter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met with one of Trump’s longest-serving advisors. We helped put together a plan to help investors capitalize on Trump’s election. And we found out these 10 stocks are the most likely to boom…Go here now to find out the names of these 10 stocks. 5/14/20215,690,000 shares $145.95 million +3.3%N/A9.4 $25.65 4/30/20215,510,000 shares $166.57 million +1.9%N/A8.4 $30.23 4/15/20215,410,000 shares $151.16 million +4.4%N/A7.5 $27.94 3/31/20215,180,000 shares $151.05 million +2.8%7.1%6.5 $29.16 3/15/20215,040,000 shares $156.44 million +0.2%6.9%6.1 $31.04 2/26/20215,030,000 shares $151.96 million -0.2%7.0%5.8 $30.21 2/12/20215,040,000 shares $151.91 million -24.1%7.0%6 $30.14 1/29/20216,640,000 shares $183.53 million -14.5%9.2%7.7 $27.64 1/15/20217,770,000 shares $200.47 million -14.6%10.8%9.9 $25.80 12/31/20209,100,000 shares $178.63 million -5.9%12.6%12.1 $19.63 12/15/20209,670,000 shares $178.70 million -1.1%13.4%14.6 $18.48 11/30/20209,780,000 shares $173.89 million -1.3%13.5%15.6 $17.78 11/15/20209,910,000 shares $165.99 million +3.9%13.7%15.6 $16.75 10/30/20209,540,000 shares $124.69 million +3.6%13.2%13.3 $13.07 10/15/20209,210,000 shares $111.99 million -1.8%12.8%12.9 $12.16 9/30/20209,380,000 shares $122.32 million -11.0%13.1%12.5 $13.04 9/15/202010,540,000 shares $139.23 million -1.8%14.6%12.1 $13.21 8/31/202010,730,000 shares $143.46 million +0.5%14.9%10.1 $13.37 8/14/202010,680,000 shares $135.21 million -1.5%14.8%9.1 $12.66 7/31/202010,840,000 shares $130.84 million -1.5%15.0%9.7 $12.07 7/15/202011,000,000 shares $130.35 million +0.6%15.2%8.9 $11.85 6/30/202010,930,000 shares $120.45 million +22.7%15.1%8.9 $11.02 6/15/20208,910,000 shares $113.25 million +20.2%12.3%7.5 $12.71 5/29/20207,410,000 shares $106.78 million +0.3%10.3%6.7 $14.41 5/15/20207,390,000 shares $108.85 million -15.5%10.2%6.9 $14.73 4/30/20208,750,000 shares $137.64 million -7.0%12.1%7.1 $15.73 4/15/20209,410,000 shares $135.50 million +1.8%13.0%8.3 $14.40 3/31/20209,240,000 shares $134.07 million -21.5%12.8%8.1 $14.51 3/13/202011,772,600 shares $179.53 million -7.0%16.3%10.5 $15.25 MYGN Short Interest - Frequently Asked Questions What is Myriad Genetics' current short interest? Short interest is the volume of Myriad Genetics shares that have been sold short but have not yet been closed out or covered. As of February 15th, traders have sold 5,430,000 shares of MYGN short. 6.09% of Myriad Genetics' shares are currently sold short. Learn More on Myriad Genetics' current short interest. What is a good short interest ratio for Myriad Genetics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. MYGN shares currently have a short interest ratio of 5.0. Learn More on Myriad Genetics's short interest ratio. Which institutional investors are shorting Myriad Genetics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Myriad Genetics: Citadel Advisors LLC, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Myriad Genetics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 6.09% of Myriad Genetics' floating shares are currently sold short. Is Myriad Genetics' short interest increasing or decreasing? Myriad Genetics saw a increase in short interest in February. As of February 15th, there was short interest totaling 5,430,000 shares, an increase of 11.7% from the previous total of 4,860,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Myriad Genetics' short interest compare to its competitors? 6.09% of Myriad Genetics' shares are currently sold short. Here is how the short interest of companies in the industry of "biotechnology" compare to Myriad Genetics: Amicus Therapeutics, Inc. (5.04%), Ligand Pharmaceuticals Incorporated (4.75%), Dynavax Technologies Co. (15.71%), BioCryst Pharmaceuticals, Inc. (8.46%), MannKind Co. (10.36%), Geron Co. (11.91%), Celldex Therapeutics, Inc. (14.40%), Novavax, Inc. (22.35%), OPKO Health, Inc. (28.72%), Innoviva, Inc. (14.50%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($25.81 billion), iShares 20+ Year Treasury Bond ETF ($10.38 billion), MicroStrategy Incorporated ($7.74 billion), AppLovin Co. ($6.32 billion), Apollo Global Management, Inc. ($5.97 billion), Super Micro Computer, Inc. ($4.89 billion), Charter Communications, Inc. ($4.52 billion), Capital One Financial Co. ($3.94 billion), Schlumberger Limited ($3.19 billion), and Reddit, Inc. ($3.01 billion). View all of the most shorted stocks. What does it mean to sell short Myriad Genetics stock? Short selling MYGN is an investing strategy that aims to generate trading profit from Myriad Genetics as its price is falling. MYGN shares are trading down $0.34 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Myriad Genetics? A short squeeze for Myriad Genetics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of MYGN, which in turn drives the price of the stock up even further. How often is Myriad Genetics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including MYGN, twice per month. The most recent reporting period available is February, 15 2025. More Short Interest Resources from MarketBeat Related Companies Amicus Therapeutics Short Interest Ligand Pharmaceuticals Short Interest Dynavax Technologies Short Interest BioCryst Pharmaceuticals Short Interest MannKind Short Interest Geron Short Interest Celldex Therapeutics Short Interest Novavax Short Interest OPKO Health Short Interest Innoviva Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:MYGN) was last updated on 3/3/2025 by MarketBeat.com Staff From Our PartnersDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredThe Deep State Surveillance Plot To Sabotage President TrumpThere's a Trump approved IRS-loophole which allows you to steer clear of government overreach and move your re...American Hartford Gold | SponsoredTrump’s Victory Could Spark Major Gains for Gold – Don’t Miss Out This "Patriot's Tax Shield" lets you defend your wealth with real, solid gold. Our exclusive, free wealth pr...American Alternative | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Myriad Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Myriad Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
